Securities Code: 002688 Securities Abbreviation: Jinhe Biotechnology
Jinhe Biotechnology Co., Ltd.
(No. 71, Xinping Road, Tuoketuo County, Hohhot, Inner Mongolia Autonomous Region)
2025 Prospectus for Issuance of Securities to Specific Targets under Simplified Procedure
(Registration Draft)
Sponsor (Lead Underwriter)
Ping An Securities
(Address: Floors 22-25, Tower B, Ping An Financial Center, 5023 Yitian Road, Futian District, Shenzhen)
August 2026
Statement
-
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the contents of this prospectus, ensuring there are no false records, misleading statements, or major omissions, and assume individual and joint legal liability for any such issues.
-
This prospectus is prepared in accordance with the "Administrative Measures for the Registration of Securities Issuance by Listed Companies" and the "Guidelines for Information Disclosure and Format of Companies Offering Securities No. 61 — Prospectus and Issuance Report for Securities Issued by Listed Companies to Specific Targets."
-
Upon completion of this issuance to specific targets under the simplified procedure, the Company shall be solely responsible for changes in its operations and earnings; investors shall bear the investment risks arising from this issuance.
-
This prospectus is the Board of Directors' explanation of this issuance; any contrary statements are false.
-
Investors with any questions should consult their stockbroker, lawyer, professional accountant, or other professional advisor.
-
The matters stated in this prospectus do not represent a substantive judgment, confirmation, approval, or registration consent by the approval authorities regarding the matters related to this issuance.
Major Matters Notice
The Company reminds investors to pay attention to the following major matters or risk factors and to read the relevant chapters of this prospectus carefully. Terms or abbreviations used in this section have the same meanings as those defined in the "Definitions" section of this prospectus.
-
The Company's 2026 First Quarter Report was disclosed on April 29, 2026. The Company achieved operating income of 741.879 million RMB, a year-on-year increase of 18.67%; net profit attributable to shareholders of the listed company was 62.2971 million RMB, a year-on-year increase of 21.87%; and net profit after deducting non-recurring gains and losses attributable to shareholders of the listed company was 60.0015 million RMB, a year-on-year increase of 22.60%. The 2026 First Quarter Report did not involve major matters affecting this issuance. The report has been disclosed on the Cninfo website (www.cninfo.com.cn).
-
Matters related to this issuance have been authorized by the 2024 Annual General Meeting and the 2025 Annual General Meeting, and approved by the 32nd meeting of the 6th Board of Directors and the 4th meeting of the 7th Board of Directors. This issuance has been reviewed and passed by the Shenzhen Stock Exchange's issuance and listing review body and has received the "Reply on Approving the Registration of Shares Issued by Jinhe Biotechnology Co., Ltd. to Specific Targets" (Zheng Jian Xu Ke [2026] No. 1934) from the China Securities Regulatory Commission (CSRC). The issuer will apply to the Shenzhen Stock Exchange and the Shenzhen Branch of China Securities Depository and Clearing Corporation for share issuance, registration, and listing.